Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.76
- Piotroski Score 4.00
- Grade Buy
- Symbol (EXAS)
- Company Exact Sciences Corporation
- Price $65.54
- Changes Percentage (-2.75%)
- Change -$1.85
- Day Low $64.61
- Day High $68.13
- Year High $79.62
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/29/2024
- Fiscal Year End N/A
- Average Stock Price Target $80.00
- High Stock Price Target $168.00
- Low Stock Price Target $60.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.31
- Trailing P/E Ratio -32.77
- Forward P/E Ratio -32.77
- P/E Growth -32.77
- Net Income $-204,149,000
Income Statement
Quarterly
Annual
Latest News of EXAS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Data shows Texas doctors perform abortions to save life of the mother, despite claims from politicians, media
Fox News requires agreement to their Terms of Use and Privacy Policy for email registration. Despite criticism, Texas pro-life laws allow doctors to perform abortions to save a woman's life. Data show...
By Fox News | 1 day ago -
The heat strikes back in North Texas
A disturbance will bring storms to North Texas, with potential downburst winds and lightning. Heat indices will rise early in the week. As fall approaches, the jet stream will shift south, increasing ...
By CBS News | 1 day ago -
Arch Manning takes over for injured Quinn Ewers, leads No. 2 Texas to 56-7 rout of UTSA
Arch Manning stepped in for an injured Quinn Ewers, leading Texas to a 56-7 win over UTSA with 4 TD passes and a rushing score. Manning showcased his talent, potentially becoming the starting QB if Ew...
By AP NEWS | 1 day ago
